Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice
Authors Zhu Y, Li ZL, Ding A, Yang H, Zhu WP, Cui TX, Zhang HT, Zhang H
Received 30 May 2019
Accepted for publication 13 September 2019
Published 22 October 2019 Volume 2019:13 Pages 3657—3667
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Melinda Thomas
Peer reviewer comments 2
Editor who approved publication: Dr Anastasios Lymperopoulos
Ye Zhu,1,* Ze-Liang Li,2,* Ao Ding,1,* Hui Yang,3,* Wei-Ping Zhu,1 Tong-Xia Cui,1 Hui-Tao Zhang,4 Hua Zhang1
1Department of Nephrology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, People’s Republic of China; 2Department of Medical Imaging, Cangzhou Hospital of Integrated Traditional Chinese Medicine-Western Medicine, Cangzhou 061001, People’s Republic of China; 3Department of Rheumatology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, People’s Republic of China; 4Center for Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ye Zhu
Department of Nephrology, The Fifth Affiliated Hospital of Sun Yat-sen University, Mei Hua Dong Road, No. 52, Zhuhai 519000, People’s Republic of China
Background: Diabetic nephropathy (DN) is a common complication of diabetes mellitus (DM) and also a major cause of end-stage renal disease (ESRD). Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and has been shown to exhibit renoprotective effects on a streptozotocin (STZ)-induced diabetic rat model. Yet, whether OM affects DN progression and renal injury in db/db mice, a type 2 diabetic murine model, has not been established.
Methods: Wild-type (n = 15) and db/db mice (n = 15) were treated with control saline or OM via oral gavage. The physiological and biochemical parameters were evaluated and histological examinations of kidney specimens were performed.
Results: Compared with saline-treated db/db mice, db/db mice administered with OM showed ameliorated diabetic physiological and biochemical parameters. In addition, OM decreased urinary albumin excretion and plasma creatinine level in db/db mice. Moreover, histologically, OM reduced glomerular hypertrophy and injury, and also ameliorated tubular injury, thus suggesting that OM improves renal function and minimizes renal pathological deterioration in db/db mice.
Conclusion: Our study reveals a beneficial role of OM in ameliorating DN in db/db mice, which is associated with its renoprotective function.
Keywords: olmesartan medoxomil, angiotensin II, renal injury, diabetic nephropathy, db/db mice
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]